Mark Rochester
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mark Rochester has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
D. Grier
3 shared publicationsG. Eure
3 shared publicationsN. Barber
3 shared publications- Oliver Kayes
Department of Urology and
3 shared publications - Peter Chin
School of Medicine, University of Wollongong & SouthCoast Urology, Wollongong, Australia
2 shared publications Ruth Doherty
Norfolk and Norwich University Hospital Norwich UK
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (11)
Long‐term educational value, clinical application and patient safety impact of a National Urology Simulation Boot Camp
Objectives: This study aimed to assess the prolonged educational usefulness, clinical utilisation and patient safety implications of a National Urology Simulation Boot Camp. Materials and Methods: We conducted a national cross‐sectional survey of previous attendees of a Urology Simulation Boot Camp (2015–2025). Perceived long‐term educational value was rated for individual modules using ordinal Likert scales. Differences across modules were examined using Friedman's test (complete cases only). Recall, clinical application and perceived patient‐care benefits were assessed descriptively. Results: A total of 162 responses were received; 135 respondents provided complete data for module‐level long‐term value and were included in the Friedman analysis. Long‐term educational value differed significantly across modules (Friedman χ 2 = 112.1, p < 0.001). Experiential modules, particularly emergency scenarios and core operative skills, achieved the highest mean ranks, whereas didactic components received lower rankings. Recall of hands‐on components was high across cohorts and was descriptively associated with reported clinical application. Curriculum relevance was rated highly, and 93.8% reported perceived benefits to patient care. Free‐text responses were consistent with these findings, commonly describing improved preparedness for early registrar responsibilities and the value of simulation‐based training. Conclusions: Trainees consistently rated experiential simulation‐based modules as having greater long‐term educational value than didactic components. These findings highlight the perceived importance of structured simulation‐based induction at entry to urology training.
- 18 November 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (11)
Open AccessLong‐term educational value, clinical application and patient safety impact of a National Urology Simulation Boot Camp
Objectives: This study aimed to assess the prolonged educational usefulness, clinical utilisation and patient safety implications of a National Urology Simulation Boot Camp. Materials and Methods: We conducted a national cross‐sectional survey of previous attendees of a Urology Simulation Boot Camp (2015–2025). Perceived long‐term educational value was rated for individual modules using ordinal Likert scales. Differences across modules were examined using Friedman's test (complete cases only). Recall, clinical application and perceived patient‐care benefits were assessed descriptively. Results: A total of 162 responses were received; 135 respondents provided complete data for module‐level long‐term value and were included in the Friedman analysis. Long‐term educational value differed significantly across modules (Friedman χ 2 = 112.1, p < 0.001). Experiential modules, particularly emergency scenarios and core operative skills, achieved the highest mean ranks, whereas didactic components received lower rankings. Recall of hands‐on components was high across cohorts and was descriptively associated with reported clinical application. Curriculum relevance was rated highly, and 93.8% reported perceived benefits to patient care. Free‐text responses were consistent with these findings, commonly describing improved preparedness for early registrar responsibilities and the value of simulation‐based training. Conclusions: Trainees consistently rated experiential simulation‐based modules as having greater long‐term educational value than didactic components. These findings highlight the perceived importance of structured simulation‐based induction at entry to urology training.
- Open Access
- 1 July 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1864-1874
The financial impact of surgical interventions for benign prostatic hyperplasia within a single NHS trust
To evaluate the financial impact of surgical modalities for benign prostatic hyperplasia (BPH) from the perspective of an NHS Trust. A retrospective analysis of patients undergoing Aquablation, Holmium Laser Enucleation of the Prostate (HoLEP) and Transurethral Resection of the Prostate (TURP) was conducted at a single NHS teaching hospital between January 2023 and June 2025. Financial data was extracted from the patient-level information and costing system, including clinical income based on Healthcare Resource Group tariffs, direct and indirect costs, and overheads. Primary outcomes were median episode clinical income, total costs, and net surplus/deficit. 436 procedures were analysed (140 Aquablation, 160 HoLEP, 136 TURP). Mean operative time was shortest for Aquablation (61.8 ± 27.0 min), while HoLEP had the shortest length of stay (0.34 ± 1.18 days). Aquablation was the only procedure to yield a median net surplus (+£1,859, IQR +785 to +2,736), whereas both HoLEP (-£157, IQR -679 to +189) and TURP (-£852, IQR -1,716 to +84) resulted in median deficits (p < 0.001). Aquablation's financial advantage was driven by its robotic-assisted classification, attracting a higher median clinical income (£7,659) than HoLEP (£3,038) and TURP (£2,997) (p < 0.001). Surplus-generating episodes were more frequent for Aquablation (83.6%) than HoLEP (28.1%) or TURP (22.1%) (p < 0.001). Major individual losses were driven by complications and prolonged admissions across all cohorts. This single-centre retrospective study focused on short-term hospital-level costs. It did not account for initial capital expenditure, long-term clinical outcomes, or Quality-Adjusted Life-Years. Under the current NHS Payment Scheme, Aquablation is the only financially sustainable surgical modality for the provider among those analysed. Its higher robotic-assisted tariff compensates for greater consumable costs. National tariff reviews may be warranted to ensure reimbursement reflects the true resource intensity of all surgical interventions. Establishing broader NHS cost-effectiveness will require long-term evaluation of clinical outcomes and retreatment rates.
- 1 July 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1864-1874
Open AccessThe financial impact of surgical interventions for benign prostatic hyperplasia within a single NHS trust
To evaluate the financial impact of surgical modalities for benign prostatic hyperplasia (BPH) from the perspective of an NHS Trust. A retrospective analysis of patients undergoing Aquablation, Holmium Laser Enucleation of the Prostate (HoLEP) and Transurethral Resection of the Prostate (TURP) was conducted at a single NHS teaching hospital between January 2023 and June 2025. Financial data was extracted from the patient-level information and costing system, including clinical income based on Healthcare Resource Group tariffs, direct and indirect costs, and overheads. Primary outcomes were median episode clinical income, total costs, and net surplus/deficit. 436 procedures were analysed (140 Aquablation, 160 HoLEP, 136 TURP). Mean operative time was shortest for Aquablation (61.8 ± 27.0 min), while HoLEP had the shortest length of stay (0.34 ± 1.18 days). Aquablation was the only procedure to yield a median net surplus (+£1,859, IQR +785 to +2,736), whereas both HoLEP (-£157, IQR -679 to +189) and TURP (-£852, IQR -1,716 to +84) resulted in median deficits (p < 0.001). Aquablation's financial advantage was driven by its robotic-assisted classification, attracting a higher median clinical income (£7,659) than HoLEP (£3,038) and TURP (£2,997) (p < 0.001). Surplus-generating episodes were more frequent for Aquablation (83.6%) than HoLEP (28.1%) or TURP (22.1%) (p < 0.001). Major individual losses were driven by complications and prolonged admissions across all cohorts. This single-centre retrospective study focused on short-term hospital-level costs. It did not account for initial capital expenditure, long-term clinical outcomes, or Quality-Adjusted Life-Years. Under the current NHS Payment Scheme, Aquablation is the only financially sustainable surgical modality for the provider among those analysed. Its higher robotic-assisted tariff compensates for greater consumable costs. National tariff reviews may be warranted to ensure reimbursement reflects the true resource intensity of all surgical interventions. Establishing broader NHS cost-effectiveness will require long-term evaluation of clinical outcomes and retreatment rates.
- Open Access
- 3 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 369
A Prospective Multicenter Randomized Study to Assess the Impact of a Novel Catheter Coating on Clinical Bacteriuria
Background: Catheter-associated urinary tract infections (CAUTIs) are a common source of morbidity and antibiotic use. Camstent Ltd. surface coated catheters aim to reduce bacterial colonization and infection. This study compares outcomes with Camstent Coated Catheters (CCC) versus standard uncoated catheters, Standard Care (SC). Objectives: The aim of the study was to investigate the reduction in bacteriuria in CCC versus SC, uncoated catheters. Methods: This is a prospective, UK, multi-center, randomized study including an Intention to Treat (ITT) population and a Per Protocol (PP) population of 200 and 188 subjects respectively. The PP population was sub-divided into primary and secondary cohorts with 107 and 81 subjects considered for study randomization receiving either a CCC or SC respectively. The primary endpoints including time to infection, number of days of infection and incidence of infection, and secondary endpoints including time to symptoms, UTI antibiotic use, patient reported outcomes like patient discomfort and catheter blockage were evaluated at days 0, 3, 5, 7, 10, 14, 21 and 28. For statistical analysis, Hodges–Lehmann and Fisher’s exact test were used. Results: The primary end points: Colonization-free rates at day 7 were higher in the CCC group than in the SC group (79% versus 46%) and the difference persisted on day 14 (69% versus 39%) (p = 0.016); the mean number of days infected during the first 14 days was lower in the CCC group than the SC group (3 versus 4.6 days) (two-sided; p = 0.0117); the infection rates at day 14 were lower in the CCC group than SC group (33% versus 50%). This trend continued at days 21 and 28, with consistently lower infection rates in the CCC group than SC group but did not reach statistical significance (p > 0.05). The secondary endpoint is in the secondary cohort: Time to the development of symptoms defined as a UTI requiring antibiotics showed that zero cases occurred in the CCC compared with the SC group (0% versus 20%) at p = 0.0054; median time to symptoms in the SC group was 9.0 days; and expanding this endpoint to include the primary cohort revealed that symptomatic infections occurred at 4% in the CCC group and 20% in the SC group (p = 0.0007) with a longer median time to symptoms in the CCC group than SC (13.5 versus 7 days); UTI antibiotic use was significantly lower in the CCC group than the SC group (4% vs. 21%). Conclusions: Compared with SC, CCCs were associated with substantial reductions in bacterial colonization, symptomatic CAUTI, and antibiotic use, supporting their adoption within strategies to prevent CAUTIs and promote antimicrobial stewardship. Trial registration: This study was registered prospectively in the Clinical Trials Registry (NCT04461262; Study Details|NCT04461262|The Impact Of A Catheter Coating On Clinical Bacteriuria|r).
- 3 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 369
Open AccessA Prospective Multicenter Randomized Study to Assess the Impact of a Novel Catheter Coating on Clinical Bacteriuria
Background: Catheter-associated urinary tract infections (CAUTIs) are a common source of morbidity and antibiotic use. Camstent Ltd. surface coated catheters aim to reduce bacterial colonization and infection. This study compares outcomes with Camstent Coated Catheters (CCC) versus standard uncoated catheters, Standard Care (SC). Objectives: The aim of the study was to investigate the reduction in bacteriuria in CCC versus SC, uncoated catheters. Methods: This is a prospective, UK, multi-center, randomized study including an Intention to Treat (ITT) population and a Per Protocol (PP) population of 200 and 188 subjects respectively. The PP population was sub-divided into primary and secondary cohorts with 107 and 81 subjects considered for study randomization receiving either a CCC or SC respectively. The primary endpoints including time to infection, number of days of infection and incidence of infection, and secondary endpoints including time to symptoms, UTI antibiotic use, patient reported outcomes like patient discomfort and catheter blockage were evaluated at days 0, 3, 5, 7, 10, 14, 21 and 28. For statistical analysis, Hodges–Lehmann and Fisher’s exact test were used. Results: The primary end points: Colonization-free rates at day 7 were higher in the CCC group than in the SC group (79% versus 46%) and the difference persisted on day 14 (69% versus 39%) (p = 0.016); the mean number of days infected during the first 14 days was lower in the CCC group than the SC group (3 versus 4.6 days) (two-sided; p = 0.0117); the infection rates at day 14 were lower in the CCC group than SC group (33% versus 50%). This trend continued at days 21 and 28, with consistently lower infection rates in the CCC group than SC group but did not reach statistical significance (p > 0.05). The secondary endpoint is in the secondary cohort: Time to the development of symptoms defined as a UTI requiring antibiotics showed that zero cases occurred in the CCC compared with the SC group (0% versus 20%) at p = 0.0054; median time to symptoms in the SC group was 9.0 days; and expanding this endpoint to include the primary cohort revealed that symptomatic infections occurred at 4% in the CCC group and 20% in the SC group (p = 0.0007) with a longer median time to symptoms in the CCC group than SC (13.5 versus 7 days); UTI antibiotic use was significantly lower in the CCC group than the SC group (4% vs. 21%). Conclusions: Compared with SC, CCCs were associated with substantial reductions in bacterial colonization, symptomatic CAUTI, and antibiotic use, supporting their adoption within strategies to prevent CAUTIs and promote antimicrobial stewardship. Trial registration: This study was registered prospectively in the Clinical Trials Registry (NCT04461262; Study Details|NCT04461262|The Impact Of A Catheter Coating On Clinical Bacteriuria|r).
- 4 June 2025
- Published by Elsevier in European Urology Focus
- Vol. 11 (4) , 571-574
Options Other than General Anaesthesia for Surgical Procedures for Bladder Outlet Obstruction
- 4 June 2025
- Published by Elsevier in European Urology Focus
- Vol. 11 (4) , 571-574
Options Other than General Anaesthesia for Surgical Procedures for Bladder Outlet Obstruction
- Open Access
- 8 September 2023
- Published by Wiley in BJUI Compass
- Vol. 5 (1) , 60-69
Prostatic urethral lift for subjects in urinary retention (PULSAR): 12‐Month results of a prospective controlled trial compared with real‐world outcomes
Objective: To examine the safety and efficacy of prostatic urethral lift (PUL) in acute urinary retention (AUR) patients within a controlled (PULSAR) and real‐world setting (Real‐World Retrospective study).Materials and methods: PULSAR was a 12‐month prospective study of PUL in AUR patients (n = 51) performed at six centres in the United Kingdom; enrolled BPH patients aged ≥50 years, with prostate volume of ≤100 cc. AUR was defined as being catheter dependent with at least one prior failed trial without catheter (TWOC) while on an alpha‐blocker. RWR consisted of 3226 consecutive PUL patients across 22 international sites treated between July 2017 and March 2020; 469 of whom were in urinary retention (RWRr), that is, catheter‐dependent at the time of their procedure. Symptom response, uroflow and catheter independence rates were compared between PULSAR and RWRr subjects. A logistical regression model was constructed to evaluate patient baseline and dynamic factors predicting success after the procedure.Results: Seventy‐three percent of PULSAR subjects were catheter independent and free from surgical reintervention at 12 months post‐PUL. Success was associated with higher voiding efficiency during the perioperative period. Slightly higher catheter‐independent rates (80%) were seen in RWRr patients; variables that influenced success included age <70 years, lower baseline prostate‐specific antigen (PSA), lower baseline post‐void residual (PVR) and shorter pre‐procedural catheter duration. Logistic regression of the combined PULSAR and RWRr retention groups revealed that procedural age <70 years and higher bladder voiding efficiency (BVE) were associated with success.Conclusions: Lower baseline PSA and PVR, younger age and shorter pre‐procedure catheter durations drove successful outcomes in AUR patients undergoing PUL. Post‐PUL voiding efficiencies may help ascertain long‐term response to treatment.
- 8 September 2023
- Published by Wiley in BJUI Compass
- Vol. 5 (1) , 60-69
Open AccessProstatic urethral lift for subjects in urinary retention (PULSAR): 12‐Month results of a prospective controlled trial compared with real‐world outcomes
Objective: To examine the safety and efficacy of prostatic urethral lift (PUL) in acute urinary retention (AUR) patients within a controlled (PULSAR) and real‐world setting (Real‐World Retrospective study).Materials and methods: PULSAR was a 12‐month prospective study of PUL in AUR patients (n = 51) performed at six centres in the United Kingdom; enrolled BPH patients aged ≥50 years, with prostate volume of ≤100 cc. AUR was defined as being catheter dependent with at least one prior failed trial without catheter (TWOC) while on an alpha‐blocker. RWR consisted of 3226 consecutive PUL patients across 22 international sites treated between July 2017 and March 2020; 469 of whom were in urinary retention (RWRr), that is, catheter‐dependent at the time of their procedure. Symptom response, uroflow and catheter independence rates were compared between PULSAR and RWRr subjects. A logistical regression model was constructed to evaluate patient baseline and dynamic factors predicting success after the procedure.Results: Seventy‐three percent of PULSAR subjects were catheter independent and free from surgical reintervention at 12 months post‐PUL. Success was associated with higher voiding efficiency during the perioperative period. Slightly higher catheter‐independent rates (80%) were seen in RWRr patients; variables that influenced success included age <70 years, lower baseline prostate‐specific antigen (PSA), lower baseline post‐void residual (PVR) and shorter pre‐procedural catheter duration. Logistic regression of the combined PULSAR and RWRr retention groups revealed that procedural age <70 years and higher bladder voiding efficiency (BVE) were associated with success.Conclusions: Lower baseline PSA and PVR, younger age and shorter pre‐procedure catheter durations drove successful outcomes in AUR patients undergoing PUL. Post‐PUL voiding efficiencies may help ascertain long‐term response to treatment.
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S75-S76
Prostatic Urethral Lift (PUL) effectiveness in real-world subjects with obstructive median lobes
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S75-S76
Prostatic Urethral Lift (PUL) effectiveness in real-world subjects with obstructive median lobes
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S77-S78
Real-world predictors of durability after Prostatic Urethral Lift (PUL)
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S77-S78
Real-world predictors of durability after Prostatic Urethral Lift (PUL)
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S73-S74
Prostatic Urethral Lift (PUL) in retention patients: 12-month outcomes from Real-World and PULSAR studies
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S73-S74
Prostatic Urethral Lift (PUL) in retention patients: 12-month outcomes from Real-World and PULSAR studies
- 22 July 2015
- Published by Wiley in BJU International
- Vol. 116 (5) , 780-790
Nephroureterectomy surgery in the UK in 2012: B ritish Association of Urological Surgeons ( BAUS ) Registry data
Objective: To report registry data obtained by the B ritish Association of Urological Surgeons ( BAUS ) for nephroureterectomy ( NU ) surgery in the UK performed between 1 J anuary and 31 D ecember 2012. Subjects/Patients and Methods: Registry data entered by each individual surgeon's team (self‐reported) on all 6042 nephrectomy surgeries reported to BAUS during 2012 were analysed to identify all NU surgery. Parameters for analysis included demographics, indication, type of surgery, histopathology and complications (Clavien system) of surgery. Data did not include tumour location or multiplicity, preoperative diagnostic evaluation or details of minimally invasive surgery ( MIS ) undertaken. Before analysis for this report a central process of ‘data‐cleansing’ was undertaken by a BAUS group to address any discrepancy between the listed surgery and the preoperative indication. Results: In all, 863 NU surgeries were included, performed by 220 consultant surgeons in 119 centres, and the median (range) number of NU per surgeon and unit was 3 (1–20) and 6 (1–29), respectively. The most common age group was 71–80 years (40%), most were male (64%), and haematuria was the most common presentation (74%). The dominant pathology was upper tract urothelial cancer (89%, 735), with final stage ≥pT2 in 47% (367), and the grade was 1, 2 or 3 in 6% (38), 36% (228) and 58% (362) respectively. Operative technique included MIS in 85% (720) and total reported operative complication rate (any Clavien) was 15% (128), of which Clavien ≥3 was reported in 4% (36), and perioperative death was reported in nine patients (1%). Advantages in favour of MIS included reduced hospital stay (median 5 vs 8 days), reduced major blood loss (3% vs 14%) and reduced transfusion requirement (6% vs 24%). In all, 76 cases (8%) were excluded from analysis based on benign pathology leading to reassignment to the ‘simple nephrectomy’ category. Conclusions: NU is currently a low‐volume operation (median 3 cases/year) within the remit of the nephrectomy surgeon, but is a safe procedure with a relatively low complication rate. Most NU surgery in the UK is now performed with laparoscopic assistance, with advantages including reduced major blood loss, reduced transfusion requirement and shorter hospital stay.
- 22 July 2015
- Published by Wiley in BJU International
- Vol. 116 (5) , 780-790
Nephroureterectomy surgery in the UK in 2012: B ritish Association of Urological Surgeons ( BAUS ) Registry data
Objective: To report registry data obtained by the B ritish Association of Urological Surgeons ( BAUS ) for nephroureterectomy ( NU ) surgery in the UK performed between 1 J anuary and 31 D ecember 2012. Subjects/Patients and Methods: Registry data entered by each individual surgeon's team (self‐reported) on all 6042 nephrectomy surgeries reported to BAUS during 2012 were analysed to identify all NU surgery. Parameters for analysis included demographics, indication, type of surgery, histopathology and complications (Clavien system) of surgery. Data did not include tumour location or multiplicity, preoperative diagnostic evaluation or details of minimally invasive surgery ( MIS ) undertaken. Before analysis for this report a central process of ‘data‐cleansing’ was undertaken by a BAUS group to address any discrepancy between the listed surgery and the preoperative indication. Results: In all, 863 NU surgeries were included, performed by 220 consultant surgeons in 119 centres, and the median (range) number of NU per surgeon and unit was 3 (1–20) and 6 (1–29), respectively. The most common age group was 71–80 years (40%), most were male (64%), and haematuria was the most common presentation (74%). The dominant pathology was upper tract urothelial cancer (89%, 735), with final stage ≥pT2 in 47% (367), and the grade was 1, 2 or 3 in 6% (38), 36% (228) and 58% (362) respectively. Operative technique included MIS in 85% (720) and total reported operative complication rate (any Clavien) was 15% (128), of which Clavien ≥3 was reported in 4% (36), and perioperative death was reported in nine patients (1%). Advantages in favour of MIS included reduced hospital stay (median 5 vs 8 days), reduced major blood loss (3% vs 14%) and reduced transfusion requirement (6% vs 24%). In all, 76 cases (8%) were excluded from analysis based on benign pathology leading to reassignment to the ‘simple nephrectomy’ category. Conclusions: NU is currently a low‐volume operation (median 3 cases/year) within the remit of the nephrectomy surgeon, but is a safe procedure with a relatively low complication rate. Most NU surgery in the UK is now performed with laparoscopic assistance, with advantages including reduced major blood loss, reduced transfusion requirement and shorter hospital stay.
- 25 March 2015
- Published by Wiley in BJU International
- Vol. 116 (1) , 131-134
Prevalence of ciprofloxacin‐resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK
Objective: To determine the efficacy of fluoroquinolone prophylaxis in patients undergoing transrectal ultrasonography ( TRUS )‐guided biopsy of the prostate in the N orwich population, and its correlation with ciprofloxacin resistance in the faecal flora. We also aimed to determine the usefulness of a pre‐biopsy rectal screen for resistant bacteria in these patients. Patients and Methods: The incidence and microbiology of sepsis after TRUS ‐guided prostate biopsies between 2007 and 2011 was audited retrospectively. Subsequently, in 2012, a prospective study was performed, collecting the same data but also culturing rectal swabs from all patients undergoing TRUS ‐guided biopsy, with a post‐biopsy follow‐up period of 6 months. All patients were given prophylactic oral ciprofloxacin, as per Trust policy (750 mg 1 h before biopsy, followed by 250 mg twice daily for 3 subsequent days). Results: Between 2007 and 2011, 3600 patients underwent TRUS ‐guided biopsy. Among these, 11 (0.3%) were admitted to hospital for post‐biopsy related sepsis but only 4 (0.1%) had ciprofloxacin‐resistant E scherichia coli confirmed from blood cultures: three had ciprofloxacin‐susceptible Enterobacteriaceae, and four had no ciprofloxacin susceptibility data. In 2012, 10 (3.7%) of 267 patients sampled before biopsy had ciprofloxacin‐resistant E . coli recovered on rectal swab culture but none of these men presented with post‐biopsy sepsis; during the 6‐month follow‐up period, seven patients were diagnosed with urinary tract infections. Conclusion: Ciprofloxacin‐resistant Enterobacteriaceae remains rare in the intestinal flora of the N orwich TRUS population, meaning that the drug remains adequate as prophylaxis. Pre‐biopsy rectal swabs may be useful for individual departments to periodically assess their own populations and to ensure their antibiotic policy remains valid. In populations where resistance is known to be highly prevalent, pre‐biopsy rectal swabs can help guide addition of further antibiotics to prevent post‐biopsy septicaemia.
- 25 March 2015
- Published by Wiley in BJU International
- Vol. 116 (1) , 131-134
Prevalence of ciprofloxacin‐resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK
Objective: To determine the efficacy of fluoroquinolone prophylaxis in patients undergoing transrectal ultrasonography ( TRUS )‐guided biopsy of the prostate in the N orwich population, and its correlation with ciprofloxacin resistance in the faecal flora. We also aimed to determine the usefulness of a pre‐biopsy rectal screen for resistant bacteria in these patients. Patients and Methods: The incidence and microbiology of sepsis after TRUS ‐guided prostate biopsies between 2007 and 2011 was audited retrospectively. Subsequently, in 2012, a prospective study was performed, collecting the same data but also culturing rectal swabs from all patients undergoing TRUS ‐guided biopsy, with a post‐biopsy follow‐up period of 6 months. All patients were given prophylactic oral ciprofloxacin, as per Trust policy (750 mg 1 h before biopsy, followed by 250 mg twice daily for 3 subsequent days). Results: Between 2007 and 2011, 3600 patients underwent TRUS ‐guided biopsy. Among these, 11 (0.3%) were admitted to hospital for post‐biopsy related sepsis but only 4 (0.1%) had ciprofloxacin‐resistant E scherichia coli confirmed from blood cultures: three had ciprofloxacin‐susceptible Enterobacteriaceae, and four had no ciprofloxacin susceptibility data. In 2012, 10 (3.7%) of 267 patients sampled before biopsy had ciprofloxacin‐resistant E . coli recovered on rectal swab culture but none of these men presented with post‐biopsy sepsis; during the 6‐month follow‐up period, seven patients were diagnosed with urinary tract infections. Conclusion: Ciprofloxacin‐resistant Enterobacteriaceae remains rare in the intestinal flora of the N orwich TRUS population, meaning that the drug remains adequate as prophylaxis. Pre‐biopsy rectal swabs may be useful for individual departments to periodically assess their own populations and to ensure their antibiotic policy remains valid. In populations where resistance is known to be highly prevalent, pre‐biopsy rectal swabs can help guide addition of further antibiotics to prevent post‐biopsy septicaemia.